3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Northrim BanCorp reported third-quarter 2026 net income of $14.4 million, or $0.63 per diluted share, down from $27.1 million, or $1.20 per share, a year earlier. The results include an $8.8 million impairment on a single $20.0 million loan relationship at Northrim Funding Services, which the company expects to reduce after-tax earnings by $6.7 million, or $0.29 per diluted share, and it says resolution will take several quarters.
Q3 2026 net income $14.4 million ($0.63 per diluted share), versus $15.3 million ($0.68) in Q2 2026 and $27.1 million ($1.20) in Q3 2025
Impairment charge of $8.8 million tied to one $20.0 million relationship; after-tax effect of about $6.7 million or $0.29 per diluted share
Net interest income rose 5% from the prior quarter to $38.9 million and 10% from a year earlier
Proposed PBCO Financial acquisition, all-stock, expected to close in the first quarter of 2027
ChronoScale Holdings reported fiscal first quarter 2027 revenue of $41.5 million, up 148% from a year earlier, driven by a new customer's AI infrastructure hardware resale arrangements. Net loss from continuing operations widened to $26.4 million, or $0.18 per share, from $11.2 million, or $0.08 per share, and Adjusted EBITDA fell to $5.9 million from $9.4 million, so shareholders face higher losses even as sales grew.
Revenue was $41.5 million versus $16.7 million in the prior-year quarter, up 148%.
Net loss from continuing operations was $26.4 million, or $0.18 per share, compared with $11.2 million, or $0.08 per share.
Total net loss was $42.5 million, including a $16.1 million loss from discontinued operations tied to the Legacy Ekso Business, which was sold on September 30, 2026.
As of August 31, 2026, cash and cash equivalents were $15.2 million; the company reported $328.2 million in aggregate customer prepayments received after quarter end.
Loop Industries reported its second quarter fiscal 2027 results for the three months ended August 31, 2026, with revenue of $117 thousand from engineering services to the India joint venture, compared with zero a year earlier. The net loss narrowed to $2.99 million from $3.20 million, and the company had total available liquidity of $1.9 million at August 31, 2026. The company also rescaled its planned India facility to 45 KTA to reduce capital needs, but its Special Committee is still seeking financing for its equity contribution.
Q2 revenue was $117 thousand, all from engineering services provided to the India JV, versus $0 in the prior-year quarter.
Net loss was $2.99 million, or $0.06 per share, versus $3.20 million, or $0.07 per share, a year earlier.
Cash operating expenses were $1.6 million, a decrease of $0.8 million year over year.
Total available liquidity was $1.9 million at August 31, 2026; the company says there can be no assurance its funding sources will be sufficient to reach commercial start-up.
Simmons First National Corporation reported third quarter 2026 net income of $47.1 million, or $0.32 diluted EPS, down from $66.7 million and $0.46 in the second quarter of 2026, while total revenue rose to $251.2 million from $248.6 million. Adjusted diluted EPS rose to $0.54 from $0.50, excluding $43.2 million in pre-tax items such as branch rightsizing, severance and certain professional services costs. For shareholders, GAAP earnings declined while adjusted earnings and net interest margin improved, and management plans to outline future financial targets at an Investor Day in December.
Net income $47.1 million in 3Q26 vs $66.7 million in 2Q26; diluted EPS $0.32 vs $0.46
Adjusted diluted EPS $0.54 vs $0.50 in 2Q26; certain items totaled $43.2 million pre-tax
Net interest margin rose 8 basis points to 3.92%; total deposits fell to $18.6 billion from $19.7 billion
Nonperforming loans rose to $179.9 million from $166.1 million; about $161 million remains under the 2026 buyback program, with no repurchases in the quarter
First Tracks Biotherapeutics agreed on October 15, 2026 to sell 6,106,870 common shares at $32.75 each to institutional investors, for expected gross proceeds of about $200 million before placement fees and expenses. The deal is expected to close on October 19, 2026, and proceeds will fund general corporate purposes, including clinical development of ANB033. The new shares are unregistered and will be issued to investors who must be covered by a resale registration statement filed within 30 days after closing, so existing shareholders face dilution from the issuance and possible future resales.
Sale of 6,106,870 common shares at $32.75 per share, for about $200 million in gross proceeds before fees and expenses
Expected closing on October 19, 2026, subject to customary conditions
Placement agents are Leerink Partners, Piper Sandler, UBS Investment Bank and Wells Fargo Securities
Company had 35,909,814 common shares outstanding as of October 12, 2026; resale registration due within 30 days after closing
Cohen & Steers reported third-quarter 2026 revenue of $157.4 million, up about 3% from the second quarter and about 11% from a year earlier, driven by higher average AUM. GAAP diluted EPS was $0.81, down from $0.95 in the second quarter and flat year over year, while adjusted diluted EPS rose to $0.89 from $0.85. AUM ended the quarter at $95.9 billion, down 4.2% from $100.1 billion, as market depreciation of $5.1 billion outweighed net inflows of $1.6 billion.
Revenue: $157.4 million, up about 3% from $152.7 million in Q2 2026 and about 11% from $141.7 million in Q3 2025
GAAP diluted EPS $0.81 vs. $0.95 in Q2 2026 and $0.81 in Q3 2025; adjusted diluted EPS $0.89 vs. $0.85 in Q2 2026
AUM $95.9 billion at September 30, 2026, down from $100.1 billion at June 30, 2026, with net inflows of $1.6 billion
Board declared a $0.67 quarterly dividend per share, paid August 20, 2026
Prudential disclosed preliminary, unaudited third-quarter 2026 figures ahead of its November 3, 2026 earnings release, showing an estimated $140 million reduction in Japan Businesses pre-tax adjusted operating income from the Prudential of Japan sales suspension. The company also estimated alternative investment income of its General Account $15 million to $35 million above near-term expectations, and it reclassified its International Businesses segment as Japan Businesses effective the third quarter of 2026. The figures are not final and financial closing procedures are not complete.
Prudential of Japan sales suspension estimated to reduce Japan Businesses pre-tax adjusted operating income by about $140 million in the quarter ended September 30, 2026, including one-time costs
General Account alternative investment income estimated at $15 million to $35 million above near-term expectations for the quarter
PGIM assets under management were $1.47 trillion as of September 30, 2026; PGIM other related revenues were about $20 million on an adjusted operating income basis
Brazil and Mexico operations moved to Divested and Run-off Businesses; AFP Habitat moved to Retirement; revised second quarter 2026 supplement furnished as Exhibit 99.1
On October 15, 2026, subsidiary NCL Corporation closed a $950.0 million offering of 8.750% senior notes due 2031, with net proceeds of approximately $941.7 million. The company used the proceeds, with cash on hand, to redeem its 6.125% notes due 2028 and to repay and prepay other borrowings, and it amended its revolving credit facility to raise lender commitments to $2,801.0 million. For shareholders, the filing shows a debt refinancing and a larger revolver, but the new notes carry a higher interest rate than the notes they replaced.
$950.0 million of 8.750% senior notes due October 15, 2031 closed October 15, 2026; net proceeds approximately $941.7 million before estimated fees and expenses.
Proceeds, with cash on hand, used to redeem all outstanding 6.125% notes due 2028 and to repay approximately $376.3 million of revolver borrowings and prepay approximately $42.2 million of export-credit facilities.
Revolving loan commitments increased from $2,486.0 million to $2,801.0 million; maturity is January 22, 2030, subject to conditions tied to 2027 exchangeable notes.
Pride of America Ship Holding and Norwegian Epic were added as guarantors; Norwegian Dawn and Norwegian Spirit were released as guarantors.
Fortune Brands signed a definitive agreement to sell its Fiberon composite decking business to a subsidiary of Inteplast Group Corporation for $160 million in cash. The company expects an additional non-cash impairment charge estimated at about $175 million to $205 million, on top of the $221.2 million impairment recorded as of June 27, 2026. Closing is subject to regulatory approval and is expected within 60 days.
Definitive purchase agreement executed October 15, 2026, with a subsidiary of Inteplast Group Corporation for $160 million in cash.
Expected additional non-cash impairment charge of approximately $175 million to $205 million relating to Fiberon.
Earlier impairment of $221.2 million recorded as of June 27, 2026, within the Outdoors segment.
Closing subject to regulatory approval and expected within 60 days.
SUNation Energy amended a secured revolving line of credit with MBB Energy, LLC, an entity controlled by two of the company's executives, extending the maturity date to April 15, 2027. The line's capacity had previously been raised to $1.5 million, and drawn loans carry 8% annualized interest, so the company's reliance on related-party borrowing continues.
Maturity date extended from October 15, 2026 to April 15, 2027, unless sooner repaid, amended or terminated
Aggregate capacity of the line of credit is $1.5 million, raised from $1 million in an April 14, 2026 amendment
Alcoa reported third quarter 2026 results on October 15, 2026, with net income attributable to Alcoa of $483 million, or $1.81 per diluted share, up from $407 million in the second quarter. Revenue fell 7% sequentially to $3.7 billion, and adjusted EBITDA excluding special items declined to $789 million from $901 million, so shareholders see higher reported profit alongside weaker sequential operating measures. The company also reaffirmed its 2026 production and shipment projections and said it closes the AliGroup acquisition in the first half of 2027.
Revenue was $3.704 billion, down from $3.966 billion in Q2 2026 but up from $2.995 billion in Q3 2025.
Adjusted earnings were $1.82 per share, down from $2.12 in Q2 2026; adjusted net income was $485 million.
Cash balance ended the quarter at $4.4 billion, including $2.6 billion of financing obtained for the AliGroup acquisition.
For Q4 2026, Aluminum segment Adjusted EBITDA is expected to face about $30 million of unfavorable raw material and maintenance impacts, and interest expense is projected at about $185 million for the year.
NextTrip reported fiscal second-quarter revenue of $546,687, down about 28% from $757,648 a year earlier, and said it deliberately prioritized platform and product work over near-term revenue. Six-month revenue rose about 122% to $1,998,422, and deferred revenue was about $1.2 million at August 31, 2026. Operating expenses, net loss and loss per share were not included and will appear in the Form 10-Q.
Q2 revenue (three months ended August 31, 2026): $546,687, versus $757,648 in the prior-year quarter, a decline of about 28%
Six-month revenue: $1,998,422, versus $896,475 in the prior-year period, an increase of about 122%
Deferred revenue of about $1.2 million at August 31, 2026, supported in part by cruise bookings, generally recognized when travel is fulfilled
Net loss, loss per share and operating expenses were not disclosed and will be included in the Form 10-Q
Mustang Bio said Nasdaq granted it an additional 180-calendar day period, until April 12, 2027, to regain compliance with the $1.00 minimum bid price rule after it missed the October 12, 2026 deadline. The company must close at or above $1.00 for at least 10 consecutive business days in that period, and it has said it may effect a reverse stock split if necessary. If it does not regain compliance, Nasdaq will issue a delisting notice, and the company says there is no assurance it will meet all continued listing requirements.
Nasdaq granted an additional 180-calendar day grace period, through April 12, 2027, letter dated October 13, 2026
Compliance requires a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days, generally no more than 20
Company has stated it may effect a reverse stock split if necessary; failure to comply would lead to a delisting notice
American Express furnished preliminary delinquency and write-off statistics for its U.S. Consumer and U.S. Small Business Card balances held for investment through September 30, 2026. Consumer and small business net write-off rates were lower in September than in July and August, while 30-day delinquency rates rose slightly, so the monthly credit picture is mixed for shareholders.
U.S. Consumer Card net write-off rate (principal only) was 1.5% in September, down from 1.7% in both August and July.
U.S. Consumer 30-day past due rate was 1.2% in September, up from 1.1% in August and July.
U.S. Small Business 30-day past due rate was 1.4% in September, up from 1.3% in August and July; its net write-off rate was 2.1%, down from 2.2% in August and 2.6% in July.
Total Card balances held for investment were $160.9 billion at September 30, 2026, up from $160.3 billion at August 31, 2026.
Recursion agreed to sell 61,540,000 new Class A common shares at $3.25 each, for expected gross proceeds of about $200 million, with closing expected October 16, 2026. The company also reported preliminary cash of about $561 million as of September 30, 2026, which it says will fund operations into 2029, and released updated Phase 1b/2 data for REC-4881 and news of a Sanofi option on a development candidate.
Offering of 61,540,000 Class A shares at $3.25 per share, with expected gross proceeds of about $200 million before fees and expenses, closing expected October 16, 2026
Executive officers and directors agreed to a 45-day lock-up on sales of company securities, subject to exceptions
Preliminary cash, cash equivalents and restricted cash of about $561 million as of September 30, 2026; company expects funding into 2029
Sanofi optioned a development candidate, triggering a $10 million milestone payment and bringing total collaboration payments to $144 million
Vivos Therapeutics agreed to issue 12,000 shares of a new Series C Convertible Preferred Stock, with a $12 million aggregate stated value and no cash paid, to acquire at least an 11% fully diluted stake in SOD Sciences and a 50% co-ownership interest in SOD's pseudohypoxia test. The preferred converts at a fixed $0.15 per share into up to 80 million common shares, which could dilute existing stockholders, while the company says the deal could raise reported stockholders' equity and help its Nasdaq compliance efforts. Closing is expected on October 15, 2026, subject to conditions including auditor concurrence and a consent from Streeterville Capital.
Vivos will issue 12,000 Series C Convertible Preferred shares with a $12 million aggregate stated value; no cash is paid by either party.
In exchange, Vivos receives 2,907,338 SOD common shares (at least 11% fully diluted) and an undivided 50% co-ownership interest in the test.
Preferred converts at a fixed $0.15 per share into up to 80,000,000 common shares; a 19.99% exchange cap applies pending stockholder approval.
Closing is expected on or about October 15, 2026, subject to conditions including Streeterville Capital's consent and Nasdaq notification.
Bank7 Corp. reported unaudited results for the quarter ended September 30, 2026, with net income of $10.20 million, up 22.25% from $8.35 million in the prior quarter, and EPS of $1.06 versus $0.87. Compared with the third quarter of 2025, net income and diluted EPS were lower, at $10.84 million and $1.13. The filing also says Century Financial shareholders and all regulatory approvals are in place for the merger, which is expected to close on November 1, 2026.
Net income of $10.20 million for Q3 2026, up from $8.35 million in Q2 2026, but down from $10.84 million in Q3 2025
EPS of $1.06 versus $0.87 in Q2 2026; diluted EPS was $1.13 in Q3 2025
Total loans of $1.63 billion, up 2.22% from $1.60 billion in Q2 2026; total assets of $2.01 billion
Century Financial merger expected to close November 1, 2026; net interest margin was 4.77% versus 5.07% a year earlier
First Horizon reported a third-quarter 2026 net loss available to common shareholders of $(94) million, or $(0.20) per diluted share, driven by $347 million in after-tax notable items tied to a pending sale of about $4.5 billion of consumer mortgages agreed in early October. Excluding notable items, adjusted diluted EPS was $0.53, down $0.01 from the second quarter, and the sale is expected to settle early in the fourth quarter.
Notable items totaled $0.73 per share, or $347 million after tax, mainly from reclassifying targeted mortgage loans to held for sale.
Adjusted diluted EPS was $0.53, down $0.01 from second quarter 2026.
CET1 capital ratio was a preliminary 10.3%, down from 10.5% in second quarter 2026.
Average client deposit balances rose $1.3 billion in the quarter.
Kimberly-Clark estimated preliminary results for the quarter ended September 30, 2026, with net sales of $4,134 million, down from $4,150 million a year earlier, and organic sales growth of negative 1.3%. Adjusted earnings per share attributable to Kimberly-Clark fell to $1.70 from $1.82, while reported diluted EPS rose to $5.37, helped by a $4.33 per share IFP transaction gain. The company said its 2026 outlook remains consistent with previous expectations, and final third-quarter results are due November 5, 2026.
Net sales were $4,134 million versus $4,150 million in the prior-year quarter; organic sales growth was negative 1.3% compared with 2.5%.
Adjusted earnings per share attributable to Kimberly-Clark were $1.70 versus $1.82; reported diluted EPS was $5.37 versus $1.34, including a $4.33 per share IFP transaction gain.
Adjusted operating profit was $677 million versus $683 million, and the company cited $106 million of Kenvue Acquisition costs in its operating profit adjustments.
The 2026 outlook was reaffirmed, and final third-quarter results will be released on November 5, 2026.
Cronos completed its acquisition of CanAdelaar B.V., a Dutch cannabis grower, on October 15, 2026, for a base price of €57.5 million plus contingent cash consideration tied to 2026 and 2027 Normalized EBITDA. The final Minister decision in a Bibob background review was still outstanding at closing, and an Addendum gives Cronos indemnities from seller Ring, subject to caps. The filing also shows CanAdelaar's Adjusted EBITDA declining from €24.2 million in the twelve months ended September 30, 2025 to €20.1 million annualized for the first half of 2026.
Base purchase price of €57.5 million, subject to closing and post-closing adjustments, plus contingent consideration equal to 50% of CanAdelaar's 2026 and 2027 Normalized EBITDA
Final Minister decision on the Bibob review was outstanding at closing; Ring indemnities cap liability at €22.5 million for the first two matters
€12.5 million proposed DCMR odor penalty treated as indebtedness and deducted from the estimated closing price
CanAdelaar Adjusted EBITDA was €20.1 million annualized for the six months ended June 30, 2026, versus €24.2 million for the twelve months ended September 30, 2025
U.S. Bancorp reported third-quarter 2026 net income attributable to the company of $2.20 billion, up 10.0% from a year earlier, with diluted earnings per share of $1.34, up 9.8%. Total net revenue rose 8.7% year over year to $7.97 billion, which the company called a record, and fee revenue grew 14.9%, helped by the BTIG acquisition and a small business credit card portfolio purchase. The filing contains no full-year guidance change, and higher expenses and a $135 million provision tied to the card portfolio purchase partly offset the gains.
Net income attributable to U.S. Bancorp was $2,202 million, up 10.0% from $2,001 million in Q3 2025.
Diluted EPS was $1.34, compared with $1.22 a year earlier and $1.35 in Q2 2026.
Noninterest expense rose 7.1% to $4,493 million, mainly due to the BTIG acquisition.
Provision for credit losses was $654 million, including $135 million for acquired loans; CET1 ratio was 10.8%.
PNC reported third-quarter 2026 net income of $2,097 million, or $4.97 per diluted share, up from $4.81 in the second quarter and $4.35 a year earlier. Total revenue fell 5% from the second quarter to $6.6 billion, mainly because of elevated second-quarter capital markets activity and Visa-related items, but rose 11% from a year earlier. The board also declared a $2.00 per share quarterly dividend.
Net income of $2,097 million, compared with $2,055 million in 2Q26 and $1,822 million in 3Q25
Diluted EPS of $4.97; $5.09 as adjusted for integration costs and significant items
Total revenue of $6.6 billion, down 5% from 2Q26 and up 11% from 3Q25
Quarterly dividend of $2.00 per share, payable November 5, 2026, to holders of record October 14, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.